Lung cancer was a death sentence. Now drugs are saving lives.

More patients can fend off the disease for months or years with targeted or immune-boosting drugs, results released this weekend at a top cancer conference showed.

Brianna Abbott (with inputs from The Wall Street Journal)
Published2 Jun 2024, 06:15 PM IST
Matt Hiznay with his wife, Ally, at his 10-year lung-cancer survivorship party in 2021. (Mandie Hiznay)
Matt Hiznay with his wife, Ally, at his 10-year lung-cancer survivorship party in 2021. (Mandie Hiznay)

There is more hope than ever for people diagnosed with the deadliest cancer.

Declines in smoking and the advent of screening and newer drugs have transformed the outlook for patients with lung cancer, once considered a death sentence. Progress against the disease has propelled the drop in overall cancer deaths in the U.S. over the past three decades.

And there is more to gain. More patients can fend off the disease for months or years with targeted or immune-boosting drugs, results released this weekend at a top cancer conference showed. That includes patients with forms of the disease that are notoriously tough to treat.

“It had such an abysmal prognosis. And now we have people who are being cured who we never thought would be cured,” said Dr. Angela DeMichele, a medical oncologist at Penn Medicine.

AstraZeneca’s drug Tagrisso can contain lung cancer nearly three years longer than chemotherapy and radiation alone for some stage-three patients, one study released Sunday showed. Another found that some patients with aggressive disease survived nearly two years longer with the company’s immunotherapy drug Imfinzi, the first advance for that lung-cancer subtype in decades.

Another study presented at the American Society of Clinical Oncology conference in Chicago found that 60% of advanced patients were alive without their disease advancing at five years after taking Pfizer’s Lorbrena, a drug that targeted a genetic mutation in their tumors. That compares with just 8% of patients on an older drug with the same target.

“These results are really outstanding,” said Dr. David Spigel, chief scientific officer at Sarah Cannon Research Institute in Tennessee, lead researcher on the Imfinzi trial. “A really major step forward in lung-cancer care.”

Tagrisso, Imfinzi and Lorbrena are all approved by the Food and Drug Administration and in use.

Lorbrena has kept Matt Hiznay’s stage-four lung cancer at bay for nine years. Hiznay, who never smoked, was diagnosed in 2011 after a persistent cough at 24 years old.

“Hearing that, you get old really fast,” he said.

But there was some good news: His tumor tested positive for something called an ALK gene mutation, a rare finding that made him eligible for a targeted drug. Hiznay’s doctor shook his hand and congratulated him on being a mutant.

Hiznay tried a string of drugs and older therapies including chemotherapy and radiation, each of which held off his disease for some time. He joined a clinical trial for Lorbrena in 2015 and has taken the drug ever since. Between treatment, Hiznay earned a doctorate, got married and had a daughter.

“It became a bit easier to see the future again,” said Hiznay, who lives in Brecksville, Ohio. He cherishes each day, even when his infant daughter wakes him up in the middle of the night.

More than 234,000 Americans are diagnosed with lung cancer annually. It is the leading cause of cancer death among men and women, killing some 125,000 Americans each year. The lung-cancer survival rate has increased by some 20% in the past five years, according to the American Lung Association.

Lung cancer has responded to newer drugs such as immunotherapies better than some other cancers, doctors said, in part because its tumors tend to have many mutations that make it easier to find and attack.

Tagrisso targets mutations on the EGFR gene, found in 15% of lung cancers in the U.S. One study presented at the conference added Tagrisso after chemotherapy and radiation for patients with the mutation whose stage-three disease was too far along for surgery. The median time before the disease advanced in those patients was more than three years, compared with just under six months for patients who weren’t on the drug.

Patients in the study were intended to take Tagrisso indefinitely, rather than the three years that many patients take the drug after surgery. A future step would be to study the costs of longer-term treatment and whether some patients could stop it eventually, said Dr. Lecia Sequist, a lung-cancer specialist at Mass General Cancer Center who wasn’t involved in the trial.

The results show how much lung-cancer treatment has changed in the past decade, she said: “It’s like Dorothy looking around and saying we’re not in Kansas anymore.”

Another study showed rare progress against small-cell lung cancer, a less common and more aggressive form of the disease that is harder to treat. AstraZeneca’s Imfinzi increased median survival to around 56 months, compared with 33 months on the standard chemotherapy and radiation alone. The trial included patients with small-cell lung cancer that hadn’t spread.

“To see something where we’re measuring benefit in years versus months is a huge step in the right direction,” said Dr. Lauren Averett Byers, a lung-cancer oncologist at MD Anderson Cancer Center in Houston, who wasn’t involved in the trial.

The FDA in May approved Amgen’s Imdelltra for more advanced small-cell lung cancer. Median survival with the drug was 14 months, with 40% of patients responding to the treatment.

About a quarter of lung-cancer patients are alive five years after diagnosis. The newer treatments can give some patients with advanced disease months or years more to live, but the cancer often comes back and becomes incurable. Many lung cancers are caught late.

“When you look at the disease statistics, you have to be humbled a little bit,” said Dr. Pasi Jänne, a lung-cancer specialist at Dana-Farber Cancer Institute in Boston. “We still have room to go.”

Through Hiznay’s 13 years with lung cancer, he has seen many fellow patients die. “The survivor’s guilt, it’s there, it’s real,” he said.

Five years after his diagnosis, Hiznay rented a brewery basement for a “One Percent” party, celebrating his victory against the odds of survival in 2011. He did it again after 10 years. He plans to be there for 15.

Catch all the Business News, Market News, Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.

MoreLess
First Published:2 Jun 2024, 06:15 PM IST
Business NewsScienceLung cancer was a death sentence. Now drugs are saving lives.

Get Instant Loan up to ₹10 Lakh!

  • Employment Type

    Most Active Stocks

    Bharat Electronics share price

    283.95
    03:58 PM | 1 OCT 2024
    -1.1 (-0.39%)

    Tata Steel share price

    167.00
    03:56 PM | 1 OCT 2024
    -1.45 (-0.86%)

    Tata Power share price

    481.00
    03:58 PM | 1 OCT 2024
    -1.7 (-0.35%)

    Zee Entertainment Enterprises share price

    140.05
    03:55 PM | 1 OCT 2024
    2.4 (1.74%)
    More Active Stocks

    Market Snapshot

    • Top Gainers
    • Top Losers
    • 52 Week High

    Caplin Point Laboratories share price

    2,080.30
    03:52 PM | 1 OCT 2024
    182.75 (9.63%)

    PB Fintech share price

    1,729.65
    03:57 PM | 1 OCT 2024
    113.65 (7.03%)

    Welspun Living share price

    175.00
    03:50 PM | 1 OCT 2024
    11.25 (6.87%)

    National Aluminium Company share price

    224.15
    03:56 PM | 1 OCT 2024
    13.75 (6.54%)
    More from Top Gainers

    Recommended For You

      More Recommendations

      Gold Prices

      • 24K
      • 22K
      Bangalore
      76,915.00-330.00
      Chennai
      76,921.00-330.00
      Delhi
      77,073.00-330.00
      Kolkata
      76,925.00-330.00

      Fuel Price

      • Petrol
      • Diesel
      Bangalore
      102.86/L0.00
      Chennai
      100.75/L-0.10
      Kolkata
      104.95/L0.00
      New Delhi
      94.72/L0.00

      Popular in Science

        HomeMarketsPremiumInstant LoanMint Shorts